[Mechanisms of acquired resistance to DNA topoisomerase I inhibitors].
The mechanisms of acquired resistance to mammalian DNA topoisomerase I inhibitor, camptothecin or its derivative (CPT-11) were described. Tumor cell lines containing altered or reduced topoisomerase I were reviewed. It might be necessary to further study on reduced inhibitor uptake and other unknown mechanism.
Okada
K
K
Dept. of Blood Transfusion Hiroshima Univ. Medical Hospital, Japan.
Andoh
T
T
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D004351:Drug Resistance; D006801:Humans; D000077146:Irinotecan; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000473:pathology; D059004:Topoisomerase I Inhibitors; D014407:Tumor Cells, Cultured / Q000187:drug effects*
D000972:Antineoplastic Agents, Phytogenic; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D004317:Doxorubicin; D002166:Camptothecin